Back to Pennsylvania

HB2162 • 2025

An Act amending the act of December 14, 1992 (P.L.1116, No.145), known as the Wholesale Prescription Drug Distributors License Act, further providing for definitions and for license application.

An Act amending the act of December 14, 1992 (P.L.1116, No.145), known as the Wholesale Prescription Drug Distributors License Act, further providing for definitions and for license application.

Healthcare
Passed Legislature

This bill passed both chambers and reached final enrollment, even if later executive action is not shown here.

Sponsor
BOROWSKI
Last action
2026-06-25
Official status
Referred to INSTITUTIONAL SUSTAINABILITY AND INNOVATION, June 25, 2026
Effective date
Not listed

Plain English Breakdown

Using official source text because the generated explanation was unavailable or could not be confirmed against the official bill text.

An Act amending the act of December 14, 1992 (P.L.1116, No.145), known as the Wholesale Prescription Drug Distributors License Act, further providing for definitions and for license application.

An Act amending the act of December 14, 1992 (P.L.1116, No.145), known as the Wholesale Prescription Drug Distributors License Act, further providing for definitions and for license application.

What This Bill Does

  • An Act amending the act of December 14, 1992 (P.L.1116, No.145), known as the Wholesale Prescription Drug Distributors License Act, further providing for definitions and for license application.

Limits and Unknowns

  • This entry is temporarily using official source text because the generated explanation could not be confirmed against the official bill text during the last sync.

Amendments

These notes stay tied to the official amendment files and metadata from the legislature.

A03371

06/02/26

06/02/26

Plain English: H2162B2805A03371 LKK:EJH 06/01/26 #90 A03371 AMENDMENTS TO HOUSE BILL NO.

  • H2162B2805A03371 LKK:EJH 06/01/26 #90 A03371 AMENDMENTS TO HOUSE BILL NO.
  • 2162 Sponsor: REPRESENTATIVE BOROWSKI Printer's No.
  • 2805 Amend Bill, page 1, lines 9 through 13, by striking out all of said lines and inserting Section 1.
  • Section 3 of the act of December 14, 1992 (P.L.1116, No.145), known as the Wholesale Prescription Drug Distributors License Act, is amended by adding a definition to read: Amend Bill, page 1, line 19; page 2, lines 1 through 10; by striking out all of said lines on said pages and inserting "Conditional license." A temporary license issued by the department to a manufacturer or a virtual manufacturer for a drug or medical device that has not yet received final approval from the United States Food and Drug Administration.
A03747

06/23/26

06/23/26

Plain English: H2162B3485A03747 AJB:EJH 06/17/26 #90 A03747 AMENDMENTS TO HOUSE BILL NO.

  • H2162B3485A03747 AJB:EJH 06/17/26 #90 A03747 AMENDMENTS TO HOUSE BILL NO.
  • 2162 Sponsor: REPRESENTATIVE FRANKEL Printer's No.
  • 3485 Amend Bill, page 1, lines 14 through 17, by striking out all of said lines and inserting Section 1.
  • The definition of "virtual "manufacturer" in section 3 of the act of December 14, 1992 (P.L.1116, No.145), known as the Wholesale Prescription Drug Distributors License Act, added October 16, 2024 (P.L.988, No.101), is amended and the section is amended by adding a definition to read: Amend Bill, page 2, line 16, by striking out "CONDITIONAL" and inserting Temporary Amend Bill, page 2, line 16, by striking out "TEMPORARY" Amend Bill, page 2, line 17, by inserting after "MANUFACTURER" where it occurs the second time under section 5(a.2) Amend Bill, page 2, by inserting between lines 19 and 20 "Virtual manufacturer." A person with a place of business located in this Commonwealth in the business of manufacturing and distributing a drug or medical device that: [(1) Holds the drug or device approval and label code or is otherwise identified on the product label from the United States Food and Drug Administration.] (1) With respect to the drug or medical device: (i) holds the applicable approval, clearance, authorization or labeler code issued by the United States Food and Drug Administration or is otherwise identified on labeling approved, cleared or authorized by the United States Food and Drug Administration; or (ii) for purposes of a temporary license, has submitted to the United States Food and Drug Administration and has pending before the United States Food and Drug Administration an application, premarket 2026/90AJB/HB2162A03747 - 1 - 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 notification, request or other submission seeking approval, clearance or authorization for the drug or medical device.

Bill History

  1. 2026-06-25 S

    In the Senate

  2. 2026-06-25 INSTITUTIONAL SUSTAINABILITY AND INNOVATION

    Referred to INSTITUTIONAL SUSTAINABILITY AND INNOVATION, June 25, 2026

  3. 2026-06-24 APPROPRIATIONS

    Re-reported as committed, June 24, 2026

  4. 2026-06-24 H

    Third consideration and final passage, June 24, 2026 (202-0)

  5. 2026-06-24 H

    (Remarks see House Journal Page ), June 24, 2026

  6. 2026-06-23 RULES

    Re-reported as committed, June 23, 2026

  7. 2026-06-23 H

    Second consideration, with amendments, June 23, 2026

  8. 2026-06-23 APPROPRIATIONS

    Re-committed to APPROPRIATIONS, June 23, 2026

  9. 2026-06-23 H

    (Remarks see House Journal Page ), June 23, 2026

  10. 2026-06-02 HEALTH

    Reported as amended, June 2, 2026

  11. 2026-06-02 H

    First consideration, June 2, 2026

  12. 2026-06-02 RULES

    Re-committed to RULES, June 2, 2026

  13. 2026-01-28 HEALTH

    Referred to HEALTH, Jan. 28, 2026

Official Summary Text

An Act amending the act of December 14, 1992 (P.L.1116, No.145), known as the Wholesale Prescription Drug Distributors License Act, further providing for definitions and for license application.

Current Bill Text

Read the full stored bill text
PRIOR PRINTER'S NOS. 2805, 3485 PRINTER'S NO. 3680
THE GENERAL ASSEMBLY OF PENNSYLVANIA
HOUSE BILL
No. 2162
Session of
2026
INTRODUCED BY BOROWSKI, FRIEL, KUTZ, VENKAT, MAYES, MERSKI,
PIELLI, HILL-EVANS, PROBST, GUZMAN, BURGOS, SANCHEZ, BRENNAN,
MADDEN, CEPEDA-FREYTIZ, GALLAGHER, BOYD, INGLIS, CURRY,
CIRESI, FLEMING AND SHAFFER, JANUARY 28, 2026
AS AMENDED ON SECOND CONSIDERATION, HOUSE OF REPRESENTATIVES,
JUNE 23, 2026
AN ACT
Amending the act of December 14, 1992 (P.L.1116, No.145),
entitled "An act providing minimum standards, terms and
conditions for the licensing of persons who engage in
wholesale distributions in interstate commerce of
prescription drugs; and making a repeal," further providing
for definitions and for license application.
The General Assembly of the Commonwealth of Pennsylvania
hereby enacts as follows:
Section 1. Section 3 of the act of December 14, 1992
(P.L.1116, No.145), known as the Wholesale Prescription Drug
Distributors License Act, is amended by adding a definition to
read:
SECTION 1. THE DEFINITION OF "VIRTUAL "MANUFACTURER" IN
SECTION 3 OF THE ACT OF DECEMBER 14, 1992 (P.L.1116, NO.145),
KNOWN AS THE WHOLESALE PRESCRIPTION DRUG DISTRIBUTORS LICENSE
ACT, ADDED OCTOBER 16, 2024 (P.L.988, NO.101), IS AMENDED AND
THE SECTION IS AMENDED BY ADDING A DEFINITION TO READ:
Section 3. Definitions.
<--
<--
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
The following words and phrases when used in this act shall
have the meanings given to them in this section unless the
context clearly indicates otherwise:
* * *
" Conditional TEMPORARY license." A temporary license issued
by the department to a manufacturer or a virtual manufacturer
UNDER SECTION 5(A.2) for a drug or medical device that has not
yet received final approval from the United States Food and Drug
Administration.
"VIRTUAL MANUFACTURER." A PERSON WITH A PLACE OF BUSINESS
LOCATED IN THIS COMMONWEALTH IN THE BUSINESS OF MANUFACTURING
AND DISTRIBUTING A DRUG OR MEDICAL DEVICE THAT:
[(1) HOLDS THE DRUG OR DEVICE APPROVAL AND LABEL CODE OR
IS OTHERWISE IDENTIFIED ON THE PRODUCT LABEL FROM THE UNITED
STATES FOOD AND DRUG ADMINISTRATION.]
(1) WITH RESPECT TO THE DRUG OR MEDICAL DEVICE:
(I) HOLDS THE APPLICABLE APPROVAL, CLEARANCE,
AUTHORIZATION OR LABELER CODE ISSUED BY THE UNITED STATES
FOOD AND DRUG ADMINISTRATION OR IS OTHERWISE IDENTIFIED
ON LABELING APPROVED, CLEARED OR AUTHORIZED BY THE UNITED
STATES FOOD AND DRUG ADMINISTRATION; OR
(II) FOR PURPOSES OF A TEMPORARY LICENSE, HAS
SUBMITTED TO THE UNITED STATES FOOD AND DRUG
ADMINISTRATION AND HAS PENDING BEFORE THE UNITED STATES
FOOD AND DRUG ADMINISTRATION AN APPLICATION, PREMARKET
NOTIFICATION, REQUEST OR OTHER SUBMISSION SEEKING
APPROVAL, CLEARANCE OR AUTHORIZATION FOR THE DRUG OR
MEDICAL DEVICE.
(2) AT NO TIME TAKES PHYSICAL POSSESSION OF ANY DRUG OR
DEVICE IN THIS COMMONWEALTH.
20260HB2162PN3680 - 2 -
<--
<--
<--<--
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
* * *
Section 2. Section 5 of the act is amended by adding a
subsection to read:
Section 5. License application.
* * *
(a.2) Conditional TEMPORARY license.--
(1) If the applicant is a manufacturer of a prescription
drug or a virtual manufacturer of a drug or medical device
that has not yet received approval from the United States
Food and Drug Administration, the department may issue a
conditional TEMPORARY license if the applicant submits all of
the following:
(i) Documentation demonstrating that an application
for approval has been submitted to the United States Food
and Drug Administration, including, where applicable:
(A) a new drug application number;
(B) an abbreviated new drug application number;
(C) a biologics license application number;
(D) a unique device identification number; o r
(E) A 510(K) PREMARKET NOTIFICATION; OR
(E) (F) other documentation acceptable to the
department demonstrating active review by the United
States Food and Drug Administration.
(ii) Documentation identifying any contract
manufacturing organization or licensed manufacturing
facility involved in the manufacture, packaging, labeling
or distribution of the drug or medical device.
(iii) Documentation demonstrating compliance with
applicable requirements of 21 U.S.C. Ch. 9 Subch. V Pt. H
(relating to pharmaceutical distribution supply chain).
20260HB2162PN3680 - 3 -
<--<--
<--
<--
<--<--
<--<--
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
(2) A conditional TEMPORARY license issued under
paragraph (1):
(i) shall expire one year after issuance unless
renewed by the department;
(ii) shall automatically expire upon denial,
withdrawal or refusal of the applicant's approval
application by the United States Food and Drug
Administration;
(iii) may not authorize commercial distribution of a
drug or device unless otherwise permitted under Federal
law; and
(iv) does not create a property interest in the
conditional TEMPORARY license and may be suspended or
revoked by the department for failure to maintain
compliance with this act or applicable Federal law.
(3) An applicant issued a conditional TEMPORARY license
under paragraph (1) shall notify the department within five
business days of:
(i) approval, denial, withdrawal or refusal of an
application by the United States Food and Drug
Administration; or
(ii) any material change to the applicant's
manufacturing or distribution arrangements.
(4) Issuance of a conditional TEMPORARY license or a
license under this subsection may not be construed as
approval, endorsement or authorization of a drug or medical
device by the Commonwealth.
(5) The department may promulgate regulations and
develop monitoring, reporting and enforcement procedures
necessary to implement this subsection.
20260HB2162PN3680 - 4 -
<--<--
<--<--
<--<--
<--<--1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
(6) Upon satisfactory proof provided by the conditional
TEMPORARY licensee to the department that all conditions for
licensure have been met, the department shall convert the
conditional TEMPORARY license into a license within 30 days.
(7) THE DEPARTMENT MAY NOT RENEW A TEMPORARY LICENSE
MORE THAN ONCE FOR THE SAME APPLICANT.
* * *
Section 3. This act shall take effect in 60 days.
20260HB2162PN3680 - 5 -
<--
<--<--
<--
<--
1
2
3
4
5
6
7
8